Tag Archives: Max Nisen

Anthem defies Wall Street, rivals, with stellar 1Q results pegged to Obamacare business

The News: Anthem Inc. (Indianapolis IN), which has 1.1 million customers in individual Obamacare plans, said it was moving ahead with its 2018 insurance filings but had told state regulators… Read more »

Cardinal Health does face plant on skanky earnings guidance; even deal for some Medtronic assets raises concerns

The News: Cardinal Health Inc. (Dublin OH) struck a deal to buy part of Medtronic PLC’s (Dublin IRL) patient monitoring and recovery unit for $6.1 billion, bringing businesses under Cardinal’s roof… Read more »

Wall Street cheers as Axovant snags biotech star David Hung; failed Alzheimer’s drug not impressed

The News: Axovant Sciences Ltd. (Hamilton Bermuda) announced that former Medivation Inc. (San Francisco) chief executive and founder David Hung has been selected as its next CEO effective April 7, 2017 sending… Read more »

Message to GOP on Trumpcare resuscitation effort: it’s dead; get over it

The News: House Speaker Paul Ryan announced a Republican agreement Thursday (April 6, 2017) on legislative language that he said will bring the chamber closer to passing a bill to… Read more »

GOP can’t handle the truth: millions to lose coverage under Trumpcare

Steve’s Take: Remember President Trump’s pre- and post-election promise, no, it sounded more like a guarantee, of “insurance for everybody?” Then last week, the Trump-backed House bill, when finally unveiled… Read more »

Icahn’s latest target, Bristol-Myers, may play hard-to-get; unless Pfizer comes a courting

The News: Activist investor Carl Icahn just announced his latest target: Bristol-Myers Squibb Co., reports the Wall Street Journal. Bristol-Myers has been the focus of several activist investors in recent… Read more »

Teva reports 4Q earnings surprise; but 2017 guidance seen “through a glass darkly.”

The News: Teva Pharmaceutical Industries Ltd. (Petach Tikva ISR) reported Monday (February 13, 2017) that fourth-quarter sales surged 33% year-over-year to $6.5 billion, topping analysts’ estimates of $6.3 billion. The company… Read more »

Pfizer stumbles to 4Q profit after rough year for Prevnar; what happened to industry leadership role?

News: Pfizer Inc.’s (New York City) key pneumococcal vaccine, Prevnar, whose sales soared through 2015, stumbled in fourth-quarter results (pdf) released last week. The blockbuster inoculation fell significantly short of Street… Read more »

Bristol Myers cuts guidance on cancer drug issues; shareholders scanning skies for vultures with deep pockets

The News: Bristol-Myers Squibb Co. (New York City) cut its earnings guidance for the year as the drugmaker contends with dimmed prospects for its top cancer drug after major setbacks… Read more »

Novartis repeats possible spinoff for Alcon eyecare unit; the best laid plans gone awry?

The News: Novartis AG (Basel CHE), which spent several years and more than $50 billion acquiring the Alcon eye-care company, signaled it’s ready to give up on most of the… Read more »